The upcoming earnings report for Globus Medical, Inc. (GMED) is scheduled for Wednesday, May 6th, with a consensus estimate EPS of $0.92.
Today, GMED is priced at $92.1, showing a decrease of $1.6 (-1.71%) from the previous close of $93.7. Trading volume is at $77,448, 7.05% relative to the average.
The latest quarterly earnings for GMED, reported on Monday, February 23rd, had a consensus estimate EPS of $1.06. The company's latest quarterly revenue and earnings call summary are forthcoming.
GMED's cash flow indicates a positive trend with free cash flow at $192.39 million and a net change in cash of $154.39 million.
In the last reporting period, GMED generated revenue of $826.39 million with a net income of $140.63 million and an EPS of $1.05.
Key ratios for GMED include a gross profit margin of 72%, return on equity of 3.07%, and a price-to-earnings ratio of 20.98.
GMED's balance sheet shows total assets of $5.30 billion, total liabilities at $729.51 million, and net debt of -$407.5 million.
This report provides insights into GMED's financial health, recent performance, and upcoming earnings outlook, indicating a mixed picture for investors.
Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. It offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative, deformity, tumors, and trauma conditions; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional pain management solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. The company also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, it distributes human cell, tissue, and cellular and tissue-based products. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.